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Pneumococcal meningitis is associated with a signiﬁcant mortality rate and neurologic sequelae. The animals received either
10μL of saline or a S. pneumoniae suspension and were randomized into diﬀerent groups: sham: placebo with dexamethasone
0.7mg/kg/1day; placebo with dexamethasone 0.2mg/kg/7days; meningitis groups: dexamethasone 0.7mg/kg/1day and dexam-
ethasone 0.2mg/kg/7days. Ten days after induction we evaluated memory and oxidative stress parameters in hippocampus and
cortex.Inthestep-downinhibitoryavoidancetask,weobservedmemoryimpairmentinthemeningitisgroupwithdexamethasone
0.2mg/kg/7days. The lipid peroxidation was increased in hippocampus in the meningitis groups with dexamethasone and in
cortex only in the meningitis group with dexamethasone 0.2mg/kg/7days. The protein carbonyl was increased in hippocampus
in the meningitis groups with dexamethasone and in cortex in the meningitis groups with and without dexamethasone. There
was a decrease in the proteins integrity in hippocampus in all groups receiving treatment with dexamethasone and in cortex in
all groups with dexamethasone (0.7mg/kg/1day). The mitochondrial superoxide was increased in the hippocampus and cortex
in the meningitis group with dexamethasone 0.2mg/kg/7days. Our ﬁndings demonstrate that dexamethasone reverted cognitive
impairment but increased brain oxidative stress in hippocampus and cortex in Wistar rats ten days after pneumococcal meningitis
induction.
1.Introduction
Streptococcus pneumoniae causes the worst acute bacterial
infection of the central nervous system (CNS) [1]. Pneu-
mococcal meningitis in adults results in cognitive speed loss
[2], intracranial complications, brain edema, hydrocephalus,
hippocampal apoptosis, and cortical necrosis [3]. Cognitive
impairments were found in one-third of patients, and for
this reason, large numbers of patients will continue to have
complaints attributable to their illness after the acute phase
of the disease [4]. The inﬂammatory host response in the
subarachnoid space seems to be associated with unfavorable
outcomes, accompanied by intrathecal production of mul-
tiple mediators, including the TNF-α,I L - 1 β IL-6 [5], and
matrix metalloproteinases; in consequence, polymorphonu-
clear leukocytes are attracted and activated. As a result, large
amounts of nitric oxide and reactive oxygen species (ROS)
areproduced[6].ThebrainisparticularlyvulnerabletoROS,
brain cells’ membranes are rich in polyunsaturated fatty
acids that can be oxidized [7] leading to lipid peroxidation,2 Oxidative Medicine and Cellular Longevity
DNA modiﬁcation, and cellular dysfunction [8]. Further-
more, treatments with antioxidants have demonstrated to
prevent the brain damage [9], attenuating meningeal inﬂam-
mation, blood-brain barrier breakdown, and intracranial
hypertension [10]. Dexamethasone is a glucocorticoid, very
well known to reduce inﬂammatory cascades, and is used
in variety of clinical conditions where their immunosup-
pressive properties are beneﬁcial [4]. However, the use
of dexamethasone in bacterial meningitis is controversial
[11]. In experimental animal model with pneumococcal
meningitis, dexamethasone inhibited the matrix metallopro-
teinase expression [12], decreased neurological sequelae, and
inhibited caspase-3 activity in adult rat model by Group B
Streptococcus [13, 14]. On the other hand, dexamethasone
as an adjuvant therapy aggravated hippocampal apoptosis,
reduced learning capacity [15], and did not prevent sen-
sorineural hearing loss in pneumococcal meningitis in infant
rats [16]. Thereby, in this study, we investigated the adjuvant
therapy with dexamethasone in cognitive performance and
oxidative stress in rats induced by pneumococcal meningitis.
2.MaterialandMethods
Male Wistar rats (3-4 months, 220–310g) were obtained
from our breeding colony (UNESC). The animals were
housed ﬁve in a cage with food and water available ad
libitum and maintained on a 12h light/dark cycle (lights
on at 7:00a.m.). All experimental procedures involving
animals were performed in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and the
Brazilian Society for Neuroscience and Behavior (SBNeC)
recommendations for animal care and approved by the
Animal Care and Experimentation Committee of UNESC,
Brazil by protocol 84/2009.
2.1. Meningitis Model. A l ls u r g i c a lp r o c e d u r e sa n db a c -
teria administrations were performed under anesthesia
consisting of an intraperitoneal (i.p.) administration of
ketamine (6.6mg/kg), xylazine (0.3mg/kg), and acepro-
mazine (0.16mg/kg) [17]. S. pneumoniae was cultured
overnight in 10mL Todd Hewitt broth medium and grown
f o ra n o t h e r6h( 3 5 ◦C, CO2 5.5%) and grown to logarithmic
phase. The culture was centrifuged for 10min at 5,000×g
andresuspendedinsterilesalinetothedesiredconcentration
and used for intracisternal injection [18, 19] containing
5 × 109 cfu/mL [14, 20]. On day 1, the rats underwent a
basilar cistern tap with a 23-gauge needle. The position of
the needle was veriﬁed by the free ﬂow of clear cerebrospinal
ﬂuid. Cerebrospinal ﬂuid was withdrawn and the animals
received either 10μL of sterile saline 0.85% as a control
(sham) or an equivalent volume of the S. pneumoniae.
Cerebrospinal ﬂuid (CSF) was obtained by intracisternal
puncture at 16h after infection, and 5mL were cultured in
serial dilutions on blood-agar plates to assess bacterial load
[18,21],followedbytheinitiationoftheantibiotictreatment
(ceftriaxone 100mg/Kg twice a day, i.p., for seven days)
[20]. The animals were randomized into diﬀerent groups:
sham: placebo group with dexamethasone (0.7mg/kg/1 day)
and placebo group with dexamethasone (0.2mg/kg/7 days)
and meningitis group with dexamethasone (0.7mg/kg/1
day)andmeningitisgroupwithdexamethasone(0.2mg/kg/7
days) [22]. Ten days after the induction of meningitis
behavioral test was performed. After the behavioral test, the
animals were sacriﬁced, and hippocampus and cortex were
isolated to the determination of thiobarbituric acid reactive
substances,proteincarbonylsgroups,sulphydrylgroups,and
mitochondrial superoxide.
2.2. Behavioral Tests
2.2.1. Step-Down Inhibitory Avoidance Task. This task eval-
uates aversive memory. The apparatus and procedures have
been described in previous reports [23]. Brieﬂy, the training
apparatus was a 50 × 25 × 25cm acrylic box (Albarsch,
Porto Alegre, Brazil) whose ﬂoor consisted of parallel caliber
stainless steel bars (1mm diameter) spaced 1cm apart. A
7cm-wide, 2.5cm-high platform was placed on the ﬂoor of
theboxagainsttheleftwall.Inthetrainingtrial,animalswere
placed on the platform, and their latency to step down on
the grid with all four paws was measured with an automatic
device. Immediately after stepping down on the grid, the
animals received a 0.4mA, 2.0s foot shock and returned
to their home cage. A retention test trial was performed
24h after training (long-term memory). The retention test
trial was procedurally identical to training, except that no
foot shock was presented. The retention test step-down
latency(maximum180s)wasusedasameasureofinhibitory
avoidance retention.
2.3. Biochemical Assays
2.3.1. Lipid Peroxidation. Lipid peroxidation was measured
by formation of thiobarbituric acid (TBA) reactive sub-
stances (TBARS) after the method of Esterbauer and Cheese-
man [24]. After brain dissection, brain structures were
washed with PBS, harvested, and lysed. TBA 0.67% was
added to each tube and vortexed. The optical density of each
solution was measured in a spectrophotometer at 535nm.
Data were expressed as nmoL of TBARS equivalents per mg
of protein.
2.3.2. Protein Carbonyl Formation. Protein carbonyl con-
tent was measured in brain homogenates using 2,4-
dinitrophenylhydrazine (DNPH) in a spectrophotometric
assay [25]. Absorbance was recorded in a spectrophotometer
at 370nm for both DNPH-treated and HCl-treated samples.
Protein carbonyl levels were expressed as nmol of carbonyl
per mg of protein. All the results were normalized by protein
concentration measured by the Lowry assay [26].
2.3.3. Sulphydryl Groups. Total thiol content (Sulphydryl
groups –SH) in the brain was determined using the 5,5-
dithiobis(2-nitrobenzoic acid) (2-nitrobenzoic acid) method
(DTNB). The conditions of DTNB measurement were as
described previously [27], with some modiﬁcations. The
absorbance at 412nm was measured and amounts of TNBOxidative Medicine and Cellular Longevity 3
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Figure 1: The step-down inhibitory avoidance. The step-down
inhibitory avoidance test showed meningitis group with dexam-
ethasone treatment (0.7mg/kg/1 day) and demonstrated group
meningitis with dexamethasone treatment (0.2mg/kg/7 days). Data
was presented as media and interquartile ranges, n = 10 rats per
group. ∗P<0.05 versus training.
formed (equivalent to the amount of sulphydryl (SH)
groups) were calculated. All the results were normalized by
protein concentration measured by the Lowry assay [26].
2.3.4. Mitochondrial Superoxide. As an index of electron
transporterchain(ETC)uncoupling,thegenerationofmito-
chondrial superoxide (O2
−) was determined as previously
described [28]. Superoxide dismutase (E.C. 1.15.1.1.) was
used at 0.1–0.3lM ﬁnal concentration as a negative control
to conﬁrm assay speciﬁcity.
2.3.5.StatisticalAnalysis. Datafromtheinhibitoryavoidance
task are reported as median and interquartile ranges and
comparisons among groups were performed using Mann-
WhitneyU tests.Thewithinindividualgroupswereanalyzed
by Wilcoxon tests. Data from the biochemical analyses were
analyzed by one-way analysis of variance (ANOVA) followed
by the Tukey test when F was signiﬁcant and are expressed
as mean ± standard deviation. All analyses were performed
using the Statistical Package for the Social Science (version
17.0) software.
3. Results
InFigure1,weshowedresultsfromthestep-downinhibitory
avoidance test 10 days after pneumococcal meningitis
induction. In the acute protocol there were not diﬀerences
between groups in the training session performance (P>
0.05). In the test session, there were not diﬀerence between
training and test in the step-down latencies in the meningitis
group (P = 0.153). However, the meningitis group with
dexamethasone treatment 0.7mg/kg/1 day showed statistical
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Figure 2: Oxidative variables. TBARS. The thiobarbituric acid
reactivespecies(TBARS)wasevaluatedinthehippocampus(a)and
cortex (b), during the treatment with dexamethasone (0.7mg/kg/1
day or 0.2mg/kg/7 days). Values are expressed as mean ± SD (n = 5
for each group). ∗Diﬀerent from sham (P<0.05), ∗∗diﬀerent from
sham with dexamethasone.
diﬀerence between training and test sessions (P ≤ 0.05).
In the repeated dexamethasone protocol, there were not
diﬀerencesbetweengroupsinthetrainingsession(P>0.05).
In the test session, there were not diﬀerence in the step-down
latency in the meningitis group (P = 0.080) and meningitis
group treated with dexamethasone 0.2mg/kg/7 days (P =
0.240) when compared to the training session. The oxidative
damage in lipids, TBARS, in hippocampus, Figure 2(a),
was increased in meningitis groups with dexamethasone
(0.7mg/kg/1dayand0.2mg/kg/7days)whencomparedwith
the sham group (P ≤ 0.05) and Figure 2(b),i nc o r t e x ,
was increased in meningitis group with dexamethasone
treatment (0.2mg/kg/7 days) when compared with the sham4 Oxidative Medicine and Cellular Longevity
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Figure 3: Protein carbonyl. The protein carbonyls was evaluated in
the hippocampus (a), and cortex (b), during the treatment with
dexamethasone (0.7mg/kg/1 day or 0.2mg/kg/7 days). Values are
expressed as mean ± SD (n = 5 for each group). ∗Diﬀerent from
sham (P<0.05), ∗∗diﬀerent from sham with dexamethasone.
(P ≤ 0.05).InFigure3(a),inhippocampus,proteincarbonyl
assays, was increased in meningitis group with adjuvant
dexamethasone treatment, respectively (0.7mg/kg/1 day and
0.2mg/kg/7 days) when compared with the sham group
(P ≤ 0.05). In Figure 3(b), in cortex, carbonyl levels were
increased in meningitis group and meningitis group with
dexamethasone treatments, respectively, with (0.7mg/kg/1
day and 0.2mg/kg/ days) when compared with the sham
group (P ≤ 0.05). The integrity of proteins was measured by
sulfhydryl (SH) groups in Figure 4(a); in the hippocampus,
there was a decrease in the integrity of proteins in all groups
with adjuvant treatment with dexamethasone and menin-
gitis group. In cortex, all the groups with dexamethasone
treatment (0.7mg/kg/1 day) were decreased in the protein
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Figure 4: Sulphydryl groups. The sulphydryl groups was evaluated
in the hippocampus (a) and cortex (b), during the treatment with
dexamethasone (0.7mg/kg/1 day or 0.2mg/kg/7 days). Values are
expressed as mean ± SD (n = 5 for each group). ∗Diﬀerent from
sham (P<0.05), ∗∗diﬀerent from sham with dexamethasone.
integrity Figure 4(b) (P ≤ 0.05). We demonstrated in
Figure 5(a), in hippocampus, and Figure 5(b),i nc o r t e x ,
that the increased activity of mitochondrial superoxide
in the meningitis group with dexamethasone treatment
(0.2mg/kg/7 days), when compared with sham group (P ≤
0.05).
4. Discussion
With S. pneumoniae proliferation in the subarachnoid space
large amounts of subcapsular bacterial components are
released, which includes lipopolysaccharide, lipoteichoic
acid, pneumolysin, and bacterial DNA [29]. Bacterial com-
ponentsarerecognizedbyToll-likereceptors(TLRs)orotherOxidative Medicine and Cellular Longevity 5
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Figure 5: Mitochondrial superoxide dismutase (SOD). The SOD
activitywasevaluatedinthehippocampus(a)andcortex(b)during
the treatment with dexamethasone (0.7mg/kg/1 day or 0.2mg/kg/7
days). Values are expressed as mean ± SD (n = 5 for each group).
∗Diﬀerent from sham (P<0.05), ∗∗diﬀerent from sham with
dexamethasone.
pathogen recognition receptors that lead to the activation
of NF-kappaB, and it triggers the inﬂammatory cytokines
expression. In consequence, polymorphonuclear leukocytes
are attracted and activated; furthermore, the induction of
nitric oxide synthase (iNOS) is expressed, producing large
amounts of superoxide anion (O2
−) and nitric oxide (NO),
leading to the peroxynitrite formation (ONOO−). As a
result, oxidative stress leads to cytokines and chemokines
activation, enhancement of neutrophil activation, lipid per-
oxidation, DNA single-strand breaks, and mitochondrial
damage [30]. Various pathophysiological alterations are
induced, such as increased blood brain barrier permeability,
brain edema, intracranial hypertension, and thrombosis,
which may cause learning deﬁcits, neuropsychiatric impair-
ment, sensory motor deﬁcits, blindness, and deafness [31].
Glucocorticoids are used in clinical conditions, where their
immunosuppressive properties are supposed to account
for their beneﬁcial eﬀects [4]. Adjunctive treatment with
dexamethasone is associated with an inﬂammatory process
reduction in the subarachnoid space [32]; it decreased the
caspase-3 activation, inhibited the MMP-9 expression in the
rat brains inoculated with S. pneumoniae [12], and improved
neurologic outcomes in meningitis [13, 14]. We veriﬁed that
treatment with dexamethasone administered in a single dose
prior the antibiotic therapy prevented the cognitive impair-
ment in animals induced with pneumococcal meningitis. At
the same time, this adjuvant treatment induced the lipid per-
oxidation and protein carbonyls, decreased cellular integrity
in hippocampus and increased mitochondrial superoxide
activity levels. It has been expressed that steroids reduce
the blood-brain permeability and thereby the antibiotics
penetration into the subarachnoid space [33]. Irazuzta et al.,
2005, veriﬁed the performance in the water maze task was
improvedinanimalstreatedwithdexamethasone,suggesting
that dexamethasone attenuates meningitis memory deﬁcits
[13]. Bacteriolytic antibiotics cause the release of bacterial
components that augment the host inﬂammatory response,
which, in turn, contributes to the brain injury in bacterial
meningitis [21]. This highly proinﬂammatory response
would be inhibited with the use of dexamethasone treatment
before the ﬁrst antibiotic dose. Leib and coworkers [15]
showed a signiﬁcantly impaired learning performance in
infected infant rats by pneumococcal meningitis treated
with dexamethasone (0.7mg/kg with an interval of 8
hours from 18 to 34h) when compared with the control
group. We also veriﬁed, in our results, that the prolonged
dexamethasone use did not prevent cognitive impairment
in animal model. In four trials including children with
Haemophilus inﬂuenzae meningitis, dexamethasone reduced
the frequency of neurological sequels and sensorineural
hearing loss [34, 35]. Likewise, in the European study, it
was showed that adjunctive therapy with dexamethasone
reduced the unfavorable outcomes rate from 25 to 15% in
adults with bacterial meningitis; adjunctive treatment with
dexamethasone was given before or with the ﬁrst antibiotics
dose [36]. Dexamethasone inhibits the production of TNF-
α and IL-1β, reduces brain edema, and limits the increase
in cerebrospinal ﬂuid lactate and leukocyte concentrations
[4]. van de Beek and colleagues, 2010 [37], published the
meta-analysis of 2029 patients from ﬁve trials. They veriﬁed
that adjunctive dexamethasone treatment in acute bacterial
meningitis therapy did not seem to signiﬁcantly reduce
death or neurological disability. There were no signiﬁcant
treatment eﬀects in any of the prespeciﬁed subgroups. The
beneﬁt of adjunctive dexamethasone treatment for all or any
subgroupofpatientswithbacterialmeningitisthusremained
unproven. We veriﬁed that treatment with dexamethasone,
with one dose, before the beginning of antibiotic therapy
reduces cognitive damage in animals induced with pneumo-
coccal meningitis.
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